PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis

BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic progressive liver disease leading to biliary fibrosis and cirrhosis. Cilofexor is a nonsteroidal farnesoid X receptor agonist that demonstrated significant improvements in liver biochemistry and markers of cholestasis in patients with PSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Trauner, Michael, Chung, Chuhan, Sterling, Kate, Liu, Xiangyu, Lu, Xiaomin, Xu, Jun, Tempany-Afdhal, Clare, Goodman, Zachary D., Färkkilä, Martti, Tanaka, Atsushi, Trivedi, Palak, Kowdley, Kris V., Bowlus, Christopher L., Levy, Cynthia, Myers, Robert P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015541/
https://www.ncbi.nlm.nih.gov/pubmed/36922785
http://dx.doi.org/10.1186/s12876-023-02653-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015541/
https://www.ncbi.nlm.nih.gov/pubmed/36922785
http://dx.doi.org/10.1186/s12876-023-02653-2

Ejemplares similares